Home › Markets › Health Care › SLDB

Solid Biosciences Inc. (SLDB)

SLDB trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · October 14, 2026
$5.82
-13.26% on the day
Market cap
$624.1M
Small cap
Revenue
No annual revenue filed since the period ending 2022-12-31
Net income
No annual revenue filed since the period ending 2022-12-31

Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026.

Profile

FieldValue
TickerSLDB on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryUnited States
IPO year2018
SEC CIK0001707502
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inDE

Financials

No annual revenue filed since the period ending 2022-12-31.

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-08-06
Latest annual report10-K2026-03-19
Latest quarterly / interim10-Q2026-08-06
Latest current report8-K2026-08-06
Latest proxyDEFA14A2026-04-23

Source: SEC EDGAR submissions feed, 734 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-20.5%
1 month-34.9%
3 months-39.8%
Year to date-3.5%
1 year-9.4%
From 52-week high-51.2%

Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
PRMEPrime Medicine Inc.$3.32-8.03%$602.2M
AURAAura Biosciences Inc.$6.27-4.13%$650.2M
ATTOAttovia Therapeutics Inc.$14.72+0.89%$672.0M
FDMT4D Molecular Therapeutics Inc.$12.36-4.92%$682.8M
CADLCandel Therapeutics Inc.$9.27-5.21%$709.3M
ETRAElectra Therapeutics Inc.$8.61-7.62%$540.4M
SANASana Biotechnology Inc.$2.41-8.02%$721.5M
DBVTDBV Technologies S.A.$9.03-5.45%$534.7M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier